Category - Markets

Markets

Echelon ups ProMetic to speculative buy but cuts PT to 60 cents

Echelon Wealth Partners upgraded ProMetic Life Sciences (TSX:PLI) to “speculative buy” from “hold” but reduced its price target to 60 cents from $1 after the company announced plans for Phase 3 testing of its anti...

December 6, 2018

Markets

Roth starts BioSig Technologies at buy; PT $14

Roth Capital Partners initiated coverage of BioSig Technologies (NASDAQ:BSGM) with a “buy” rating and $14 price target. The stock closed at $3.97 on Dec. 4. BioSig is a medical device company developing the PURE EP...

December 6, 2018

Markets

Roth starts CorMedix at buy; PT $6

Roth Capital Partners launched coverage of CorMedix (NASDAQ:CRMD) with a “buy” rating and price target of $6. The stock closed at $1.35 on Dec. 4. CorMedix is developing Neutrolin for the prevention of catheter-related...

December 6, 2018

Markets

BTIG starts Valeritas Holdings at buy; PT $1

BTIG initiated coverage of Valeritas Holdings (NASDAQ:VLRX) with a “buy” rating and price target of $1. The stock closed at 39 cents on Dec. 3. Valeritas sells V-Go, the only pump on the market for Type 2 diabetes...

December 4, 2018

Markets

Maxim starts Agile Therapeutics at buy; PT $3

Maxim Group initiated coverage of Agile Therapeutics (NASDAQ:AGRX) with a “buy” rating and $3 price target. The stock closed at 81 cents on Nov. 28.

November 29, 2018

Markets

JP Morgan starts Orchard Therapeutics at OW; PT $25

JP Morgan launched coverage of Orchard Therapeutics (NASDAQ:ORTX) with an “overweight” rating and December 2019 price target of $25. The stock closed at $16.75 on Nov. 22. Analyst Anupam Rama writes that Orchard, in a...

November 26, 2018

Markets

JP Morgan starts Audentes Therapeutics at OW; PT $35

JP Morgan initiated coverage on Audentes Therapeutics (NASDAQ:BOLD) with an “overweight” rating and December 2019 price target of $35. The stock closed at $23.91 on Nov. 22. “Audentes shares have pulled back 40%-plus...

November 26, 2018

Markets

BTIG ups Helius Medical to buy; PT $14

BTIG upgraded Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) to “buy” from “neutral,” with a $14 price target, after the company closed a $17.5-million stock offering. The stock closed at $8 on Nov. 19. Analyst Dr...

November 21, 2018

Markets

HCW assumes coverage of Caladrius Biosciences at buy; PT $18.50

H.C. Wainwright analyst Joseph Pantginis assumed coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and price target of $18.50. The stock closed at $4.52 on Nov. 19. Caladrius is developing two...

November 20, 2018

Markets

Mackie ups Bellus Health PT to $2.20 from $1

Mackie Research raised its price target for Bellus Health (TSX:BLU) to $2.20 from $1 after the company reported Phase 1 top-line results of BLU-5937 for the treatment of chronic cough. In the study, BLU-5937...

November 20, 2018

Category - Markets

Subscribe